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Abstract 
 
Growing evidences suggest that the multifunctional protein E4F1 is involved in 
signalling pathways that play essential roles during normal development and 
tumorigenesis. Here, we have generated E4F1 conditional knock-out mice to address 
E4F1 functions in vivo in newborn and adult skin. E4F1 inactivation in the entire skin or 
in the basal compartment of the epidermis induces skin homeostasis defects, as 
evidenced by transient hyperplasia in the interfollicular epithelium and alteration of 
keratinocyte differentiation, followed by loss of cellularity in the epidermis and severe 
skin ulcerations. E4F1 depletion alters Epidermal Stem Cells (ESC) clonogenic activity 
ex vivo and ends in exhaustion of the ESC pool in vivo, indicating that the lesions 
observed in the E4F1 mutant skin result, at least partly, from cell autonomous 
alterations in ESC maintenance. Clonogenic potential of E4F1 KO ESC is rescued by 
Bmi1 over-expression or by Ink4a/Arf or p53 depletion. Skin phenotype of E4F1 KO 
mice is also delayed in animals with Ink4a/Arf and E4F1 compound gene deficiencies. 
Our data identify a novel regulatory axis essential for ESC-dependent skin homeostasis 
implicating E4F1 and the Bmi1-Arf-p53 pathway. 
 
Abbreviations: 
ESC, Epidermal Stem Cells; HF, Hair Follicle; 4OHT, 4-Hydroxy Tamoxifen; IFE, 
Interfollicular Epithelium; K5, K6, K10, K14 and K15, Keratin-5, 6, 10, 14 and 15 
respectively; KO, Knock-Out; LRC, Label Retaining Cells; RERT , Cre-ERT2 knock-in mice; 
TAC, Transit Amplifying Compartment.  
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/body Introduction: 
E4F1 is an ubiquitously expressed transcription factor of the Gli-Kruppel family that 
was identified as a cellular target of the adenoviral oncoprotein E1A (1). While several 
cellular targets of E1A (E2F/pRB, CBP/p300, PCAF, CtBP, ATF/Creb etc…) have been 
extensively studied and recognized as central regulators of cell proliferation and survival, 
E4F1 biological functions remained poorly investigated. E4F1 is a multifunctional protein 
with transcriptional and atypical ubiquitin E3-ligase activities. E4F1-mediated ubiquitylation 
of p53 does not lead to proteasomal degradation but modulates p53 transcriptional activities 
involved in alternative cell fates: growth arrest or apoptosis (2). The notion that E4F1 plays an 
important role in the p53 pathway is reinforced by other reports showing that E4F1 not only 
directly interacts with p53 itself (2, 3) but also with regulators/effectors of this pathway, 
including p14ARF (4), the polycomb member Bmi1 (5), and the p53 target gene FHL2 (6). 
Nevertheless, E4F1 functions most likely extend beyond the regulation of p53. Thus, physical 
interactions between E4F1 and components of other oncogenic pathways have been reported, 
including RASSF1A (7), pRB (8), HMGA2 (9) and Smad4 (10).   
Using a gene targeting approach in mouse, we previously showed that E4F1 
constitutive inactivation results in embryonic lethality around the time of implantation. E4F1 
KO blastocysts in culture exhibit mitotic defects including lagging chromosomes, chronic 
activation of the mitotic checkpoint, and massive cell death (11). More recently, shRNA-
mediated partial depletion of E4F1 was also shown to rescue hematopoietic stem cell (HSC) 
exhaustion in mouse resulting from inactivation of the polycomb member Bmi1 (5), 
suggesting an important role for E4F1 in HSC homeostasis. 
To date, little information is currently available regarding the in vivo functions of 
E4F1 in adult tissues. Here, we generated several mouse strains to explore the roles of E4F1 
in skin homeostasis. 
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Constant renewal of the Interfollicular Epithelium (IFE) and of Hair Follicles (HF) 
relies on the recruitment of epidermal stem cells (ESC) located in the basal layer of the IFE 
and in the bulge region of HF, respectively. ESC fuel the highly proliferative transit 
amplifying compartments (TAC) in the basal layer of the IFE and in the bulb of the HF. TAC 
cells then embark on differentiation programs to generate the spinous, granular and cornified 
layers in the IFE or the different lineages of the mature HF (12-14). Several essential 
molecular circuitries that orchestrate epidermal stem cells maintenance have been previously 
described, including p63-, BMP-, TGF-ß-, Wnt/ß-catenin-, and Notch-initiated signalling 
cascades (12, 15, 16). 
Here, we show that inactivation of E4F1 in the entire skin or in the basal compartment 
of the epidermis results in severe epidermal defects both in neonates and in adult mice, 
revealing a yet unidentified regulatory axis essential for ESC-dependent skin homeostasis 
implicating E4F1 and the Bmi1-Ink4a/Arf-p53 pathway.  
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Results: 
 
Inactivation of E4F1 induces transient hyperplasia in the epidermis followed by 
permanent loss of epidermal cells and severe skin ulcerations. 
We first investigated E4F1 expression pattern in epidermis. Immunohistochemical 
analyses of murine and human skin sections showed nuclear expression of E4F1 in the basal 
and suprabasal layers of the interfollicular epithelium (IFE), as well as in the bulb and bulge 
regions of the hair follicle (HF) (Fig. 1A). 
To analyse the role of E4F1 in skin homeostasis, we generated two mouse models with 
homozygote deletion of the E4F1 gene in the entire skin or in the epidermis only, using 
conditional (Cre-ERT2) and tissue specific (K5-Cre) Cre/Lox-P systems, respectively. In short, 
we first generated E4F1-/flox mice harboring E4F1 conditional knock-out allele (Fig. S1) and 
inter-crossed them with Cre-ERT2 KI/KI mice (RERT) which express tamoxifen-inducible Cre 
recombinase-ERT2 fusion protein under the control of the ubiquitously active RNA polII 
promoter, i.e. in all tissues (17). As expected, topical applications of 4-hydroxy-tamoxifen 
(4OHT) on the tail skin or on a shaved area of the back skin of adult E4F1-/flox; RERT animals, 
resulted in efficient Cre-mediated recombination of the E4F1 locus in the skin, as monitored 
on genomic DNA, mRNA and protein samples prepared from the treated area (Fig. S1).  
Between 1 and 2 weeks after 4OHT-administration, E4F1-depleted back skin 
thickened, became wrinkled and ruffled. Those early lesions evolved 1 to 2 weeks later into 
severe skin ulcerative lesions (Fig. 1B). Strikingly, E4F1 inactivation in unshaved skin tail of 
E4F1-/flox; RERT animals resulted in complete alopecia 6 weeks after 4OHT applications (Fig. 
1C). Histological analyses revealed that skin thickening was the result of a massive 
hyperplasia of the epidermis with increased cellularity in the IFE and the infundibulum (Fig. 
1D). Consistent with the observed hyperplasia, an abnormal proportion of epidermal cells 
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were proliferating in E4F1 KO skin, as indicated by increased immunostaining of skin 
sections for the proliferation marker Ki67 (Fig. 1D), and anti-BrdU staining performed on 
skin sections harvested shortly after injection of animals with BrdU (Fig. S2). This phenotype 
was skin autonomous since similar hyperplasia was recapitulated upon engraftment of E4F1-
/flox; RERT p1 neonatal back skin onto nude mice (Fig. S3). At later time points (3 to 4 weeks 
after 4OHT administration), the initial hyperplasia of E4F1 KO; RERT skin was followed by 
broad disorganisation of the IFE and massive hyperkeratosis associated with partial or 
complete loss of cellularity in the IFE (Fig. 1D).  
To further show that the observed phenotypes resulted from epidermis specific 
defects, we crossed E4F1-/flox mice with Keratin 5-Cre (K5-Cre) transgenic mice expressing 
Cre in the epidermal basal cell layer, from E15.5 onwards (18). E4F1-/flox; K5-Cre neonates 
exhibited efficient E4F1 gene inactivation in the epidermis as shown by 
immunohistochemical staining and western-blot analyses with anti-E4F1 antibodies (Fig. 1E 
and S1). 3 to 4 days after birth, these animals exhibited epidermal hyperplasia, and died with 
acute symptoms of dehydration (Fig. 1F). As in E4F-/flox; RERT animals, this hyperplasia was 
associated with hyperproliferation of epidermal cells, as shown by increased Ki67 staining 
(Fig. 1G). Consistent with increased proliferation, E4F1 KO epidermis also exhibited higher 
mitotic index, as illustrated by increased number of phospho histone H3 (Ser10, PHH3) 
positive basal cells (Fig. S5). Of note, we previously showed that E4F1 KO blastocysts also 
exhibited PHH3-positive cells (11), but in this case, cells were blocked in mitosis with 
abnormal mitotic figures. We did not observe abnormal mitotic figures in E4F1 KO epidermal 
basal cells, indicating that the increased mitotic index likely reflects over-proliferation of 
basal cells, rather than mitotic progression defects. 
In order to bypass neonatal lethality of E4F1 KO; K5-Cre animals and investigate later 
phenotypes, we engrafted E4F-/flox; K5-Cre or control skins onto nude mice. 2 weeks after 
 7
engraftment, E4F1 KO; K5-Cre skins failed to regenerate a normal epidermis. Similarly to the 
late phenotype of E4F-/flox; RERT animals, E4F1 KO, K5-Cre engrafted skins exhibited 
marked hypocellularity in the epidermis, hyperkeratosis and severe ulcerative lesions (Fig. 
1H). Of note, hair follicles were also lacking in E4F1 KO, K5-Cre engrafted skins. 
Collectively, our data indicate that E4F1 inactivation results in transient hyperplasia but 
ultimately leads to permanent loss of epidermal cells in the IFE and HFs.  
 
E4F1 inactivation results in expansion of the basal cells compartment of the 
epidermis and in abnormal keratinocyte differentiation in vivo. 
We next assessed which epidermal cell populations were present in these hyperplasic 
lesions. In both 4OHT-treated E4F1-/flox; RERT and E4F1-/flox; K5-Cre epidermis, cells of the 
hyperplasic IFE stained positive for the basal cell-specific keratin-14, integrin-α6, markers 
(Fig. 2A and S4). Expression of these markers extended to upper cellular layers, in contrast to 
normal IFE of control animals where their expression was restricted to the basal cell layer. In 
addition, E4F1-floxed IFE massively expressed keratin-6 (Fig. 2B and S4), which expression 
is normally restricted to sweat glands and HF in normal skin but can be expressed in the IFE 
undergoing abnormal proliferation or wound healing (19). Collectively, these analyses 
indicated that E4F1 inactivation in the IFE first resulted in massive expansion of 
keratinocytes with basal/TAC properties.  
In addition to this massive expansion of basal cells, we noticed the absence of the 
suprabasal and granular layers as illustrated by the lack of expression of early (keratins 1 and 
10), as well as late differentiation markers (involucrin, loricrin, filaggrin) in E4F1 KO 
epidermis in both E4F1flox; K5-Cre and E4F1flox; RERT models (Fig. 2B, S4). No significant 
cell death was observed among highly proliferative cells of the IFE during the development of 
hyperplasia, as revealed by immunostaining of skin sections for the presence of activated 
 8
caspase 3- or TUNEL-positive cells. Therefore, it is likely that hyperproliferative 
keratinocytes present in hyperplasic lesions had finally undergone an abnormal differentiation 
program of stratification, rather than apoptosis, leading to the observed hyperkeratosis. These 
data indicate that E4F1 inactivation strongly perturbates both the proliferation and 
differentiation of epidermal lineages in vivo leading to a strong alteration of skin homeostasis. 
 
E4F1 inactivation induces epidermal stem cell defects. 
We next investigated the mechanisms by which E4F1 inactivation in the IFE led to a 
massive but transient expansion of the basal/TAC compartment, followed by its exhaustion. 
Several scenarios could explain this sequence of events. First this could reflect an increase in 
the intrinsic capacity of basal/TAC keratinocytes to proliferate. However, this is unlikely, 
since E4F1 depletion in freshly isolated populations of primary keratinocytes in culture did 
not recapitulate the massive over-proliferation observed in skin sections, as illustrated by 
FACScan analyses of BrdU/Propidium Iodide- (PI) or PHH3/PI-labelled keratinocytes 
isolated from E4F1-/flox; RERT or control p1 neonates (Fig. S5). Similar conclusions were 
obtained in primary human keratinocytes upon shRNA-mediated depletion of endogenous 
human E4F1 (Fig. S5). These observations, together with the withering and transient aspect of 
the hypertrophy phenotypes led us to investigate an alternative hypothesis involving 
perturbations of the resident stem cells (ESC). Several aspects of E4F1 KO phenotypes are 
reminiscent of skin lesions observed in KO animals exhibiting stem cell defects. Hence, 
conditional perturbation in the epidermis of several key signalling molecules, including the 
small GTPase Rac1, Myc, Smad4, NFATC1, leads ESC to exit their normal 
microenvironment (“niche”) to enter into the TAC where they become transiently 
proliferating keratinocytes upon exposition to natural pro-mitogenic signals present in this 
amplification compartment (20-24). This results in transient hyperplasia followed by a 
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permanent exhaustion of the epidermal stem cell pool and loss of renewal capacity of the 
epithelium. 
To address this scenario, we first performed standard in vitro clonogenic assays on 
feeder layers with total primary keratinocytes isolated from in vivo recombined hyperplasic 
regions of E4F1-/flox; RERT adult mice, as well as from E4F1-/flox; K5-Cre p1 neonates or 
control littermates. After 10 to 15 days in culture, typical holoclones, corresponding to the 
long-term clonal outgrowth of epidermal cells with stem cell properties (25, 26) were detected 
in controls but not in E4F1 KO conditions in both models (Fig. 3A). Importantly, similar 
results were recapitulated when E4F1 inactivation was induced ex vivo by adding 4OHT in 
the culture medium of E4F1-/flox; RERT cells (Fig. 3A), showing that these defects were stem 
cell autonomous. Similarly, clonogenic assays performed with primary human keratinocytes 
transduced ex vivo with E4F1 shRNA constructs showed that partial E4F1 depletion resulted 
in a 3 fold reduction in the number of holoclones (Fig. 3B). 
We next investigated whether E4F1 inactivation also resulted in exhaustion of the 
stem cell pool in vivo by analysing expression of various ESC markers. FACscan analyses of 
dissociated epidermis revealed that E4F1-/flox; K5-Cre neonatal epidermis contained fewer 
ESC co-expressing the CD34 surface marker and high levels of α6-integrin (CD34+/α6high) 
than control epidermis (8% +/- 2 vs 1,5% +/- 1, n=3) (Fig. 3C). Similarly, immunostainings 
performed on back skin sections or on whole mount of tail epidermis harvested from adult 
E4F1-/flox; RERT animals 4 to 6 weeks following E4F1 inactivation, showed loss of 
expression of the HF bulge markers CD34 and keratin-15 (Fig. 3D and S6). 
To confirm these HF ESC defects in vivo, we crossed E4F1-/flox; RERT animals with 
Keratin15-EGFP (K15-GFP) transgenic mice expressing the GFP reporter under the control 
of the keratin-15 promoter (27). In 7 to 12-week-old K15-GFP; E4F1+/flox; RERT control 
animals, GFP expression was restricted to the bulge region of unsynchronized HF. In contrast, 
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complete loss of GFP-positive cells was observed 4 to 6 weeks after E4F1 inactivation in 
E4F1 KO; RERT animals, confirming the exhaustion of the HF ESC (Fig. 3E). Finally, we 
tracked HF bulge/ESC as BrdU Long Term Retaining Cells (LRC) using an in vivo labelling 
protocol that marks self-renewing and multi-potent epidermal cells (26, 28). E4F1-/flox; RERT 
and E4F1+/flox; RERT neonates were injected with BrdU and after a chase period of three 
months, the poorly proliferative adult ESC were identified on whole mounts of tail epidermis, 
as BrdU-positive LRC. 2 to 3 weeks after E4F1 inactivation the LRC zone extended and an 
increased numbers of LRCs were co-labeled with Ki67 in E4F1 KO HF as compared to 
control HF (Fig. 3F early and S7), suggesting that E4F1 inactivation induced HF ESC to 
transiently proliferate. At later time points (6 weeks after 4OHT), whereas LRCs were still 
restricted to the bulge of control HF, BrdU staining finally disappeared in the E4F1 KO HF 
(Fig. 3F late), supporting the notion that the end result of E4F1 inactivation was an 
exhaustion of the ESC pool. Finally, consistent with the role of ESC in regenerating the 
various epithelial cell types of hairy skin after injury (26), we also observed that wound 
healing was strongly altered in E4F1 KO skin (figure S8). Altogether, these data indicate that 
E4F1 is essential for ESC maintenance in vivo and ex vivo, and strongly suggest that the 
hyperplasia and following loss of cellularity of E4F1 KO epidermis, are primarily due to cell 
autonomous perturbations of the ESC pool that aliments TAC compartments. 
 
Down regulation of the Bmi1-Ink4a/Arf-p53 axis partly rescues ESC-clonogenic 
potential and skin lesions of E4F1 KO. 
We next addressed the molecular pathway by which E4F1 could regulate ESC 
maintenance. E4F1 associates with the polycomb member Bmi1 and the tumor suppressors 
Arf, p53 and pRb (2-5, 8). Although there are evidences that these factors have independent 
functions, they define a well established functional cascade with Bmi1 triggering the 
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repression of the Ink4a/Arf locus whose products, p19Arf and p16Ink4a, act as potent inhibitors 
of the p53- and pRb-dependent activities, respectively (29). Several reports suggest that the 
negative regulation of Ink4a/Arf expression may be a central event in stem cell renewal in 
several tissues (30-33) including epidermis (34). Strikingly, we observed that E4F1 KO 
primary keratinocytes exhibited enhanced Ink4a and Arf mRNA levels compared to control 
cells (Fig. 4A), suggesting that the deregulation of the Ink4a/Arf locus might be involved in 
E4F1 KO phenotype. Consistent with this hypothesis, clonogenic assays performed with 
primary keratinocytes isolated from E4F1-/flox; RERT; Ink4a/Arf-/- compound mice showed 
that Ink4a/Arf inactivation partly restored long-term outgrowth of E4F1 KO ESC ex-vivo (Fig. 
4B, C). The number of viable clones growing in this condition was similar to that obtained 
from control skin. 
Importantly, the in vivo skin phenotype of E4F1 KO mice was also delayed in animals 
with Ink4a/Arf and E4F1 compound gene deficiencies. Hence, the initial epidermal 
hyperplasia of 4OHT-treated E4F1-/flox; RERT; Ink4a/Arf-/- animals was almost undetectable at 
early time points following E4F1 inactivation (Fig. 4D, early), compared to control 
littermates with E4F1 KO only. Nevertheless, at later time points, these animals ended up to 
develop a moderate hyperplasia and hyperkeratosis (Fig. 4D, late).  
To provide further evidence for a role of the Ink4a/Arf–pRb/p53 cascades in E4F1 KO 
phenotype, we next tried to rescue the clonogenic potential of E4F1 KO ESC by targeting 
Bmi1, one of the main upstream regulator of the Ink4a/Arf locus. Transduction of 
keratinocytes by retroviruses expressing Bmi1 rescued long-term outgrowth and clonogenic 
potential of E4F1 KO cells (4OHT-treated E4F-/flox; RERT keratinocytes) (Fig. 5A and 5C). 
To assess which Ink4a/Arf downstream targets might be involved, clonogenic assays 
were also performed upon shRNA-mediated (lentiviral vectors) depletion of either murine 
RB1 or p53 in E4F1 KO keratinocytes. p53 (Fig. 5B and 5C) but not pRb depletion restored 
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clonal outgrowth of E4F1 KO keratinocytes, highlighting the role of the Bmi-Arf-p53 axis 
rather than the Bmi-p16-pRb axis in E4F1 KO skin phenotypes. Of note, E4F1 KO rescued 
clones that developed upon inactivation of Ink4a/Arf, depletion of p53 or overexpression of 
Bmi1, all remained significantly smaller in size, compared to those growing from control cells 
(Fig. 4B-C, 5A-B), suggesting that E4F1 might also impinge on other molecular circuitries 
that orchestrate ESC maintenance. 
Altogether, our data provide the first evidence that E4F1 is essential for ESC-
dependent skin homeostasis and identify a novel regulatory axis involved in this process 
implicating Bmi1 and the Arf-p53 pathway. 
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Discussion 
 
In vivo functions of E4F1 remain poorly documented. Here, we created E4F1 
conditional KO mice and reported that E4F1 inactivation in the epidermis led to neonatal 
lethality that resulted from skin homeostasis defects. We found that E4F1 depletion in E4F1 
KO; K5-Cre neonates first led to a rapid thickening of the IFE associated with increased 
numbers of highly proliferative keratinocytes in the basal cell layers (TAC compartment) of 
the IFE. Comparable results were obtained upon E4F1 inactivation in adult skin obtained by 
topical applications of 4OHT on the back skin of E4F1-/flox; RERT mice. In both E4F1 KO 
models, hyperplasia was transient and followed by a severe disorganization and almost 
complete loss of viable epithelial cell layers in the IFE and HF. In addition, perturbations of 
epidermal differentiation were observed in E4F1 depleted epidermis, in both models.   
Strikingly, E4F1 depletion in vitro, in freshly isolated populations of murine or human 
primary keratinocytes in culture, did not recapitulate the over-proliferation observed in skin 
sections, ruling out the possibility that the hyperplasia originates from an intrinsic increase in 
the proliferation capacity of E4F1 KO TAC keratinocytes. As described for other gene 
deficiencies in epidermis (20, 22), our data rather suggest that E4F1 KO phenotypes resulted 
from cell autonomous perturbations in resident stem cells. Indeed, E4F1 depletion in vivo or 
ex vivo turned out to dramatically impair the clonogenic potential of both murine and human 
epidermal cell populations. In addition, a strong reduction in the expression of various ESC 
markers was observed in vivo in E4F1 KO skins. Finally, BrdU labelling of LRC suggested 
that E4F1 KO HF stem cells first exited their normal location in the bulge region of the HFs 
to enter in a transient phase of proliferation, before disappearing. As predicted by this stem 
cell-oriented scenario, exhaustion of the resident stem cell pool in E4F1 KO skin ultimately 
led to a complete loss of cellularity in the IFE and alteration of wound healing.  
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 Seeking for the pathway by which E4F1 could regulate ESC maintenance, we found 
that the clonogenic potential of E4F1 KO ESC was restored upon targeting of the Bmi1-
Ink4a/Arf-p53 axis but not by pRb depletion, highlighting the role of the Bmi-Arf-p53 axis 
rather than the Bmi-p16-pRb axis in E4F1 KO skin phenotypes. Consistently, E4F1 
inactivation correlated with increased Ink4a/ARF expression and our in vivo data showed that 
the development of hyperplasia was delayed and reduced in animals with Ink4a/Arf and E4F1 
compound gene deficiencies. It remains unclear how this protein network impinges on ESC 
homeostasis and ultimately raises the question about the physiological functions of this Bmi1-
Ink4a/Arf-p53 axis in ESC. Although poorly documented, it has been suggested that it might 
play its usual "gate-keeper" function in these cells, notably in response to genotoxic or 
developmental stresses, as illustrated in mice with dysfunctional telomeres (35, 36) or in p63 
KO mice (34, 37). As described in other tissues, it is also formally possible that the Bmi1-
ARF-p53 protein network plays a role in the normal program of ESC self-renewal and 
maintenance. Hence, in absence of acute genotoxic stress, inactivation of p53 or Ink4a/Arf has 
been shown to impact on the self-renewal capacity of hematopoietic multipotent progenitors 
(38) and neural stem cells (39). Even more intriguing is the recent finding that p53 KO 
favours symmetric divisions and self-renewal capacity of mammary gland progenitor cells 
(40). The latter observation raises questions about similar roles of p53, and indirectly E4F1, in 
the epidermis where proper columnar stratification and tissue organization are driven, at least 
in part, by oriented, asymmetric cell divisions (41, 42). 
Our data also highlight the complexity of E4F1 connections with the polycomb family 
member Bmi1. Indeed, others have shown that shRNA-mediated depletion of E4F1 can 
rescue premature senescence of Bmi1 KO hematopoietic stem cells and restore the viability of 
animals transplanted with those rescued cells, in a Ink4a/Arf- and p53-independent manner 
(5). Our data indicate that the genetic links between E4F1 and Bmi1 in stem cell maintenance 
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are complex and might differ from one tissue to the other since in epidermis, we clearly 
observed that Bmi1 ectopic overexpression partly rescued stem cell defects of E4F1 KO ESC. 
Of note, we currently do not rule out that E4F1 might also exert yet unidentified additional 
cellular functions independent from Bmi1 and the Arf-p53 axis. Supporting this notion, we 
found that targeting the Bmi1-Arf-p53 axis did not fully restore ESC clonal outgrowth and 
normal skin phenotype. Animals with Ink4a/Arf and E4F1 compound gene deficiencies ended 
up to develop a moderate hyperplasia and hyperkeratosis at late time points. Likewise, in 
clonogenic assays, E4F1 KO rescued clones that developed upon depletion of p53 or 
Ink4a/Arf, or upon over-expression of Bmi1, all remained significantly smaller in size, 
compared to those growing from control cells. Therefore, in addition to its connection with 
the Bmi1-Arf-p53 cascade, one could hypothesize that E4F1 might also impinge on other 
hitherto described molecular circuitries that orchestrate epidermal stem cells maintenance, 
including TGFß-, Wnt/ß-catenin-, or Notch-initiated signalling cascades (12-14). 
Interestingly, a physical interaction of E4F1 with Smad4 has recently been shown in BMP-
mediated regulation of myogenic differentiation (10). Further studies will be required to 
evaluate whether this interaction is also implicated in epidermal homeostasis. 
In conclusion, the roadblock to developing an E4F1 conditional KO mouse has been 
overcome and provides the first evidence, that E4F1, through its connection with the Bmi1 
and the Ink4a/Arf-p53 axis, is an important player of stem cells-dependent skin homeostasis. 
This finding, together with previous reports showing that E4F1 is targeted by several 
oncoproteins and tumor suppressors, also raise an interesting question about E4F1 potential 
implication in the development/maintenance of cancer stem cells which presence is suspected 
in several cutaneous malignancies, including skin carcinoma and malignant melanoma. 
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Material and Methods: 
 
Ethics Statement 
All experiments involving mice were approved by Montpellier's ethic committee for animal 
warefare. 
Generation of E4F1-/flox mice and experimental treatment of mice 
Generation of the E4F1flox allele and of E4F1-/flox mice are detailed in supplementary 
informations (SI). E4F1-/flox mice were crossed with Cre-ERT2 knock-in mice (RERT) (17) or 
Keratin5-Cre transgenic mice (18) to obtain E4F1-/flox; RERTKI/KI animals, and E4F1-/flox; K5-
Cre animals, respectively. E4F1flox; RERT mice were also crossed with homozygous 
Keratin15-EGFP transgenic mice (Jackson lab) (27) to generate E4F1flox; RERTKI/KI; K15-
GFP animals and with Ink4a/Arf -/- mice (43) to generate E4F1flox; RERTKI/KI; Ink4a/Arf -/- 
animals. E4F1 recombination in adult E4F1flox; RERT skin was induced by topical 
applications of 4-hydroxy Tamoxifen (4OHT) (Sigma) (2mg dissolved in ethanol 
per application per day, 4 applications total), on the shaved back skin or the tail. For skin 
grafting experiments, dorsal skin from E4F1flox; RERT or E4F1flox; K5-Cre neonate donors 
were transplanted onto athymic nude recipient mice (Charles River), as previously described 
(44). For visualisation of BrdU-label-retaining cells (LRC), ten days old mice were injected 
with BrdU (50mg/kg of body weight, Sigma) every 12 hours for a total of four injections. To 
achieve short-term labeling of cells undergoing DNA synthesis in vivo (for IHC experiments), 
BrdU (50mg/kg of body weight) was injected intra-peritoneally, 4 hours prior to euthanasia.  
Histochemistry, immunolabelling of skin sections and whole mounts 
Immunohistochemistry of skin sections was performed as described in SI with the following 
primary antibodies: anti -E4F1 (B-21 rabbit polyclonal) generated by our laboratory, -Ki67 
(#SP6, Neomarkers), -keratin 6 (#SPM269, Abcam), -keratin10 (#PRB-159P, Covance), -
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involucrin (#Sc15230, Santa Cruz), -CD34 (RAM34, BD Pharmingen), and -keratin 15 
(#LHK15, Vector Laboratories). Immunohistofluorescence stainings with anti-α6-integrin 
(#GoH3, BD Biosciences) and anti-keratin 14 (#AF64, Covance) were performed on 10μm 
cryosections fixed for 10 minutes in 100% acetone. BrdU-positive cells were detected using 
anti-BrdU antibody (BD Biosciences). Whole mounts of tail epidermis and detection of LRC 
were prepared as described previously (28) and pictures were generated using a Zeiss 510 
confocal microscope and presented as Z-stack projections after deconvolution with Imaris 
software. 
Culture of primary keratinocytes and clonogenic assays 
Murine primary keratinocytes were isolated from newborn skin after overnight treatment with 
dispase (5 mg/mL, Roche) or from adult back skin after trypsin-EDTA overnight treatment, 
and grown in calcium-free EMEM medium (Biowhittaker, Lonza), containing 10% calcium-
free FCS (Sigma) and 10 µg/ml murine EGF (Roche). Cre-mediated recombination of E4F1 
flox alleles were achieved by adding 4OHT (1 µM, Sigma) in the culture medium. Human 
primary keratinocytes were isolated from skin biopsies obtained after medical surgery and 
cultured in Green medium containing 1,2 mM calcium as previously described (45) and 
according to Helsinki Declaration. Clonogenic assays were perfomed as described in SI. 
Colonies were fixed with 4% PFA and stained with 1% Rhodamine B (Sigma). Quantitative 
analysis of the total number and size of clones was performed with ImageJ. 
Retroviral and lentiviral particles productions and infections 
Viral particles were produced as described in SI, with the following constructs: pMSCV-
Bmi1 (29), pMKO vector encoding either control or anti human E4F1 shRNAs (sequences 
available upon request); pLKO1 encoding shRNAs directed against murine RB1 or p53 
(Sigma mission shRNA clones, NM_011640.1-625s1c1), or control irrelevant sequence.  
Western blotting 
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Total cell extracts were prepared in 50 mM Tris-HCl, pH 7.4, 100 mM NaCl, 5 mM EDTA, 
0,5% NP40, supplemented with protease inhibitors (Complete, Roche). Immunoblots were 
probed with primary antibodies directed against E4F1 (8), p53 (1C12, Cell signalling), Bmi1 
(#F6, Millipore), β-actin (Sigma) 
FACScan analyses 
Freshly isolated cell suspensions were incubated with FITC-conjugated anti-CD34 (RAM34, 
BD Biosciences) and PE-Cy5-conjugated anti-α6-integrin primary antibodies for 30 minutes 
at 4°C. For cell cycle analyses, formalin-fixed cells were incubated with anti-BrdU or anti-
phospho-serine 10 histone H3 (6G3 #9706, Cell Signalling) and PI (Sigma) as previously 
described (2). Cells were analysed on a FACS Calibur (Becton Dickinson) and data were 
processed with Flowjo software (Treestar). 
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Figure legends:  
 
Figure 1. E4F1 inactivation triggers transient hyperplasia of the epidermis followed by 
permanent loss of epidermal cells and severe skin ulcerations. (A) Immunohistochemical 
(IHC) analysis of E4F1 expression in human skin or murine back skin and hair follicle (HF). 
Scale bar = 40µm. The dotted line indicates the dermis-epidermis junction. d: dermis. (B) 
Macroscopic alterations of back skin of adult E4F1-/flox; RERT mice 7 (early) or 15 days (late) 
after Cre-mediated E4F1 inactivation. (C) Representative picture of E4F1flox; RERT tails at 
late time points (6 weeks) after 4OHT applications. (D) Hematoxylin and eosin (H/E) staining 
(upper panels) and Ki67 IHC analysis (lower panels) of dorsal skin sections prepared from 
4OHT-treated E4F1-/flox; RERT adult mice at early and late time points. Left panels show 
similar analyses performed on 4OHT-treated E4F1+/flox; RERT control animals.  Scale bar = 
20µm. (E) IHC analysis of dorsal skin sections from E4F1+/flox and E4F1-/flox; K5-Cre 
neonates using anti-E4F1 antibody. Scale bar = 40µm. (G) Photograph of representative 
E4F1+/flox and E4F1-/flox; K5-Cre neonates (P4) showing acute symptoms of dehydration. (F) 
H/E staining (upper panels) and Ki67 IHC analysis (lower panels) of dorsal skin sections 
prepared from E4F1flox; K5-Cre P4 neonates. Scale bar = 20µm. (G) Back skin from 
E4F1+/flox; K5 or E4F1-/flox; K5 P1 neonates engrafted onto recipient nude mice. Photographs 
of representative engrafted skin, 2 weeks after engrafment and H/E stained sections. Scale bar 
= 40µm. 
 
Figure 2. E4F1 inactivation results in expansion of the basal cells compartment of the 
epidermis and in abnormal keratinocyte differentiation in vivo. (A) E4F1 inactivation 
results in hyperproliferation of keratin14- and α6-integrin-positive basal/TAC cells. 
Immunostainings of dorsal skin sections from E4F1+/flox and E4F1-/flox; K5-Cre neonates with 
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anti-keratin 14 (K14) and anti-α6 integrin (α6) antibodies. (B) Immunohistochemical analysis 
of dorsal skin sections from E4F1+/flox and E4F1-/flox; K5-Cre neonates with anti-Keratin6 
(K6), anti-Keratin10 (K10) or anti-involucrin (invol) antibodies. Scale bar = 40µm. 
 
Figure 3. E4F1 inactivation results in epidermal stem cells exhaustion in vivo and ex 
vivo. (A) Clonogenic assays performed with primary murine keratinocytes prepared from 
back skin of E4F1flox; RERT adult mice 6 days after 4OHT applications (in vivo), or from 
E4F1flox; RERT neonatal skins and treated with 4OHT in culture medium, 24 hours after 
plating (ex vivo). Assays were also performed with primary keratinocytes isolated from 
E4F1flox; K5-Cre neonates (P1). Rhodamine B staining was performed after 15 days of 
culture. Data shown are representative of experiments performed in duplicates and repeated at 
least 3 times. Scale bar = 1cm. (B) Clonogenic assays (left panel) performed with human 
primary keratinocytes transduced with retroviral vectors expressing shRNAs targeting either 
human E4F1 (shE4F1) or non relevant sequence (shCtrl). Quantification (right panel) of total 
number and size (diameter, in mm) of clones from 3 independent experiments. (C) 
Multiparameter FACScan analyses of primary keratinocytes isolated from E4F1flox; K5-Cre 
P3 neonates after α6-integrin and CD34 immunostainings. The percentage of α6high/CD34+ 
epidermal stem cells is indicated (Average of 3 independent experiments +/-SD). (D) 
Immunohistochemical analyses of back skin sections from E4F1flox; RERT adult mice, 3 
weeks after 4OHT applications with antibodies directed against the stem/bulge specific 
markers CD34 (upper panels) and keratin-15 (K15, lower panels). Arrows indicate K15- or 
CD34-positive stem cells located in the bulge region of hair follicles. Scale bar = 80µm. (E) 
Whole mounts of tail epidermis prepared from E4F1flox; RERT; Keratin15-GFP mice 4 weeks 
after 4OHT applications. White arrows point K15-GFP+ ESC that locate in the bulge region 
of HF in control animals (E4F1+/flox) treated with 4OHT (left panels). DAPI staining was 
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performed to show HF morphology. Scale bar = 80 µm. (F) Analyses of Long term BrdU-
Retaining Cells (LRC) in whole mounts of tail epidermis prepared from E4F1flox; RERT 16-
week old mice at different time points after 4OHT applications. Anti-BrdU (green) and anti-
Ki67 (Red) immunostainings of control and E4F1 -/flox; RERT HF 3 (early) or 6 (late) weeks 
after E4F1 inactivation showing transient hyperproliferation followed by loss of LRC (white 
arrows). LRC locate in the bulge region of HF from control skin treated with 4OHT for 6 
weeks (E4F1+/flox, left panels). Scale bar = 80µm.  
 
Figure 4. Deletion of the Ink4a/Arf locus partially rescues E4F1 KO skin defects in vivo 
and ex vivo. (A) Quantitative analyses of Ink4a and Arf mRNA levels in E4F1flox; K5-Cre 
freshly isolated primary keratinocytes. (B) Clonogenic assays performed with E4F1flox; 
RERT; Ink4a/Arf-/- or E4F1flox; RERT; Ink4a/Arf+/+ primary keratinocytes in presence of 
4OHT. One representative experiment of 3 independent experiments performed in duplicates. 
Quantitative analyses of the number and size (diameter, in mm) of clones was performed after 
15 days in culture. (C) High magnification photograph of representative clones. Scale bar = 
0,5 mm. (D) H&E stainings of dorsal skin sections prepared from 4OHT-treated E4F1flox; 
RERT; Ink4a/Arf+/+ 12-week old mice (upper panels) or E4F1flox; RERT; Ink4a/Arf-/- mice 
(lower panels). The early epidermal hyperplasia of 4OHT-treated E4F1-/flox; RERT; 
INK4a/ARF-/- animals was reproducibly less severe and delayed compared to animals lacking 
E4F1 only (E4F1-/flox; RERT; INK4a/ARF+/+). 
 
Figure 5. Down-regulation of the Bmi1-Arf-p53 axis rescues E4F1 KO ESC defects. (A) 
Primary keratinocytes isolated from E4F1flox; RERT neonates were transduced with control 
(pMSCV) or Bmi1 encoding retroviruses (Bmi1) and used for clonogenic assays in presence 
of 4OHT. (B) Clonogenic assays performed with E4F1flox; RERT primary keratinocytes 
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transduced with control (shCtrl) or p53 (shp53) shRNAs encoding lentiviruses in presence of 
4OHT. In A-B, photographs (upper panels) and quantifications (lower panels) of one 
representative experiment. 3 independent experiments were performed in duplicates. 
Quantitative analyses of the number and size (diameter, in mm) of clones were performed 
after 10 days. (C) Western blot analyses showing ectopic overexpression of Bmi1 (left panels) 
in rescued E4F1 KO clones, or efficient shRNA-mediated depletion of p53 (center panels) in 
rescued E4F1 KO clones (right panels).  
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Supplementary Materials & methods 
 
Generation of E4F1-/flox mice  
The E4F1 targeting construct was generated by cloning 129/SvJ murine genomic E4F1 
sequences (11) into the pDT915 targeting vector. Lox-P sites were introduced before exon 4 
and after exon 14 as indicated in supplemental figure S1. A hygromycin-TK cassette flanked 
by two FRT sequences was also added after the polyA signal of the E4F1 gene. The targeting 
vector was linearized by NotI and electroporated in J1 ES cells (129/SvJ). The later were 
selected with hygromycin B (130μg/ml, Calbiochem) for a week before clonal amplification. 
Correct targeting of the E4F1 locus was assessed on genomic DNA prepared from 
hygromycin-resistant ES clones by southern blotting using probes corresponding to 5’ 
(400bp) and 3’ (360bp) flanking sequences of the E4F1 gene (Figure S1). Targeted ES cells 
were electroporated with a Flipase expressing vector (gift of Dr. Dymecki S.) and selected 
using Ganciclovir (4μM) to enrich for clones in which the hygromycin-TK cassette was 
deleted. Several E4F1+/flox ES clones displaying a normal karyotype, were subsequently 
injected into C57Bl/6 blastocysts. Chimeric mice were mated with C57Bl/6 mice for germline 
transmission of the E4F1 flox allele. Heterozygous mutant mice E4F1+/flox and E4F1+/- were 
interbred to generate E4F1-/flox animals. E4F1 recombination was assessed by immunoblotting 
or by quantitative PCR analysis on skin genomic DNA using primers specific for the E4F1 
locus, as described in Supplemental Fig. S1C-E (primer A: 5’-GGCTGCTGCGTGGATTTC, 
B: 5’-GCTAGGTAGGGTAGGAGGCTGTCT, C: 5’-ACCGGCGTGTTCACTCAGAC, D: 
5’-GCAGAACTGGCACACGTGG, E: 5’-TTCGGTATAGTGTTGAGG, F: 5’-
AGGGGCTGGGCTACAATGG). 
Genotyping 
E4F1flox; RERT mice were genotyped by PCR on tail genomic DNA using the following 
primers: i) E4F1 wild type (E4F1+) and conditional knock-out Flox alleles (E4F1flox): 5’-
CCTTGAGCACGGAGGAGAGC-3’ and 5’-GCCCTAGCCTGCTC-TGCCATC-3’. ii) E4F1 
constitutive knock-out allele (E4F1-): 5’-CACTGCCTTGGAGGACTTTG-3’ and 5’-
CCTCTGTTCCACA-TACACTTCATTC-3’. iii) wild type and knock-in RERT alleles: 5’-
GTCAGTACACATACAGACTT-3’, 5’-TGAGCGAACAGGGCGAA-3’ and 5’-
TCCATGGAGCACCCAGTGAA-3’. iv) keratin5-Cre transgene: 5‘-
AACATGCTTCATCGTCGG-3’ and 5‘-TTCGGATCATCAGCTACACC-3’.  v) keratin15-
GFP transgene: 5’-CTACGGCGTGCAGTGCTTCAGC-3’ and 5’-
GGCGAGCTGCACGCTGCGTCCTC-3’. vi) Ink4a/Arf alleles: wild type 5’-
ATGATGATGGGCAACGTTC-3’ and 5’-CAAATATCGCACGATGTC-3’; knock-out: 5’-
CTATCAGGACATAGCGTTGG-3’ and 5’-AGTGAGAGTTTGGGGACAGAG-3’. 
Histochemistry, immunolabelling of skin sections and whole mounts 
Skin biopsies were either fixed in 4% neutral-buffered formalin (24h) and paraffin embedded, 
or frozen in Tissue-Tek OCT (Sakura) for cryosections. Paraffin-embedded tissues were 
sectioned and processed for immunohistochemistry (IHC) or hematoxylin and eosin (H/E) 
stainings. IHC was performed on 4μm sections using appropriate primary antibodies and the 
corresponding biotinylated secondary antibody coupled to streptavidin-peroxidase complex 
(ABC Vectastain kit, Vector Laboratories). Revelation was performed using the peroxidase 
substrate DAB (Vector Laboratories). All secondary antibodies were diluted at 1/200 for 
immunohistochemistry (DAKO) and 1/1000 for immunohistofluorescence (Alexa-
Invitrogen). Apoptotic cells were detected using TUNEL staining kits (Roche) or by IHC with 
anti-caspase 3 antibody. 
Culture of primary keratinocytes and clonogenic assays 
For cell cycle analyses, BrdU (10 mM, Sigma) was added in the culture medium for 24 hours. 
For clonogenic assays, 2000-10000 total primary keratinocytes per well were plated on a 
confluent feeder layer of inactivated J2-3T3 fibroblasts (3 hour-treatment with mitomycin C 
at 4µg/ml, Sigma) grown on collagen-I-coated 6-well plates, at 32°C, 8% CO2 (mouse 
keratinocytes) or at 37°C, 10% CO2 (human keratinocytes). Clonogenic assays were 
performed in calcium-free DMEM-HamF12 (3:1) (Invitrogen), containing 10% calcium-free 
FCS (Sigma), 4mM L-Glutamine, 110mg/l Na Pyruvate, 8 ng/ml Choleratoxine, 0.4 µg/ml 
Hydrocortisone, 5 µg/ml Insulin (Sigma), 10 µg/ml murine EGF.  
Retroviral and lentiviral particles productions and infections 
Retroviral and lentiviral particles were produced in 293T cells by transient transfection using 
Jet-PEI reagent (Ozyme) of gag/pol, env-VSV-G, and indicated viral constructs. 48 hrs after 
transfection, viral supernatants were harvested and added on primary keratinocytes overnight 
with polybrene at 8μg/ml (Sigma). Antibiotic selection of transduced primary murine 
keratinocytes was performed 48 hours later with puromycin (1,25 µg/mL, pLKO1), or 
blasticidin (5µg/mL, pMSCV). 
 
Legends of Supplementary figures.  
Figure S1. Generation and validation of E4F1 conditional knock-out mice. (A) Schematic 
representation of the unmodified (upper), the targeting vector (middle), and recombined E4F1 
flox allele (lower). (B) Homologous recombination was verified on both ends by southern 
blotting using 5' (left panel) and 3' (right panel) external probes. (C) The hygromycin-
thymidine Kinase (Hygro-TK) resistance cassette was removed in vitro after a second round 
of electroporation of homologous recombinant ES clones using the Flpe recombinase (upper 
panel). Schematic representation of the floxed E4F1 allele after Cre-mediated recombination 
(lower panel). (D) Cre-mediated recombination of the E4F1flox allele in skin. Quantitative (left 
panel) or semi-quantitative (right panel) PCR analyses were performed on genomic DNA 
extracted from back skin of E4F1+/- or E4F1-/flox; RERT adult mice after topical application of 
4OHT, or from back skin of E4F1+/- or  E4F1-/flox; K5-Cre P1 neonates. The primer pairs used 
for PCR amplifications are indicated by arrows in (C). Note that primers pair A/B generates a 
PCR amplicon only after Cre-mediated recombination. Normalisation for equal amount of 
genomic DNA in those assays was controlled with primers (E/F) located in the non-
recombined region of the E4F1 locus. (E) Immunoblots showing E4F1 expression after Cre-
mediated recombination in primary keratinocytes isolated from E4F1flox; RERT, and treated 
with 4OHT, or from E4F1flox; K5 neonatal epidermis (right panel). ns: non-specific signal. 
 
Figure S2. E4F1 inactivation results in hyperproliferation of epidermal cells. 
Immunofluorescent images of dorsal skin sections prepared from 4OHT-treated E4F1flox; 
RERT adult mice injected with BrdU (4h), immunostained with anti-BrdU (red) antibody and 
co-stained with DAPI (blue). The dashed line indicates the basal membrane and interface 
between epidermis (top) and dermis (bottom). Scale bar = 50 µm. Genotype of the analysed 
mice is indicated. Histogram shows the quantification of the percentage of BrdU-positive 
cells in a representative experiment.  
 
Figure S3. E4F1 inactivation results in skin autonomous effects in the RERT model. 
Back skin from E4F1+/flox; RERT or E4F1-/flox; RERT P1 neonates was engrafted onto 
recipient nude mice and treated with 4OHT. Photographs at low (left panels) or higher 
(middle panels) magnification of representative engrafted skin, 2 weeks after E4F1 
inactivation. H/E stained sections of engrafted skins showing hyperplasia of E4F1 depleted 
epidermis (right panels). Scale bar = 40µm. 
 
Figure S4. E4F1 inactivation results in expansion of the basal cells compartment of the 
epidermis and in abnormal keratinocyte differentiation. (A) E4F1 inactivation results in 
hyperproliferation of keratin14- and α6-integrin-positive basal/TAC cells. Immunostainings 
of dorsal skin cryosections from E4F1+/flox and E4F1-/flox; RERT mice with anti-keratin 14 
(K14) and anti-α6 integrin (α6) antibodies. Scale bar = 40µm. (B) Immunohistochemical 
analysis of dorsal skin sections from E4F1+/flox and E4F1-/flox; RERT mice with anti-Keratin6 
(K6), anti-Keratin10 (K10) or anti-involucrin (invol) antibodies. Scale bar = 40µm. 
 
Figure S5. E4F1 inactivation does not enhance the short term proliferation of primary 
keratinocytes in culture. (A) E4F1 inactivation in vitro does not result in murine 
keratinocyte hyperproliferation. Cell cycle profiles of murine E4F1+/flox or E4F1-/flox; RERT 
primary keratinocytes after 5 days of culture in presence of 4OHT. The percentage of cells in 
each phase of the cell cycle was determined by FACS scan analyses after Propidium Iodide 
(PI)/BrdU co-staining. (B) E4F1-depletion in vitro does not result in human keratinocyte 
hyperproliferation. PI/BrdU co-staining profiles of human primary keratinocytes transduced 
with retroviral vectors expressing either a shRNA targeting human E4F1 (shE4F1) or a 
control shRNA (shCtrl). Western blot analysis (right panels) of total protein extracts showing 
efficient E4F1 depletion. (C) Anti-Phospho Histone H3 / PI labelling and FACScan analyses 
of murine E4F1+/flox or E4F1-/flox; RERT primary keratinocytes after 5 days of culture in 
presence of 4OHT. Nocodazole treated cells (Noco, 10µM) were used as positive control. (D) 
Immunohistochemical analysis of dorsal skin sections from E4F1+/flox or E4F1-/flox; K5-Cre P1 
neonates with anti-Phospho Histone H3 antibody. The number of PPH3 positive cells per field 
is indicated. 
 
Figure S6. E4F1 inactivation results in loss of Keratin15 stem cell marker expression. 
Immunostaining of HF with anti-keratin15 (K15, red) in whole mounts of tail epidermis 
prepared from E4F1-/flox; RERT and control mice 6 weeks after 4OHT applications. Small 
inset represents the same HFs after anti-integrinα6 (α6, green) and DAPI costaining (blue) to 
show general morphology. HF K15+ bulge region is indicated by a white bracket. Scale bar = 
50 µm. 
 
Figure S7. E4F1 inactivation triggers hyperproliferation of LRC. Analysis of BrdU-
labelled LRC cells (green) and of proliferative cells (Ki67, Red) in whole mounts of tail 
epidermis prepared from E4F1-/flox; RERT mice 2 weeks after 4OHT applications. Lower 
magnification image of the same HF after DAPI staining (blue) to show general morphology. 
BrdU and Ki67 double positive HF LRC stem cells are indicated by white arrows. Scale bar = 
50 µm. 
 
Figure S8. E4F1 inactivation alters wound healing. A punch was made on the back skin 
of E4F1+/flox and E4F1-/flox; RERT mice treated with 4OHT and its closure observed at the 
indicated times.   
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